Grieco M, Giorgi A, Gentile MC, dErme M, Morano S, Maras B, Filardi T (2019) Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Lower-dose protocols may allow for longer-term use with fewer side effects, which matters because inflammation-driven damage accumulates slowly over time
- Monocytes* (MON)
GCGR agonism can increase energy expenditure and stimulate hepatic glucose production, lipolysis, amino acid breakdown and suppression of hepatic fat accumulation
Additionally, patients taking multiple medications should be evaluated for potential drug interactions or additive effects, particularly if they are also taking statins, which have well-established myopathic potential
Whether it converts into meaningful market share will hinge on execution and how quickly heavyweights like Sandoz bring their own semaglutide products to pharmacy shelves.